title: [Microorganisms isolated from middle ear cultures and their antibacterial susceptibility in patients with chronic suppurative otitis media].
abstract: OBJECTIVE
  This study sought to determine causative microorganisms of chronic suppurative otitis media and their antibacterial susceptibility.
  
  
  METHODS
  Bacteriologic results of middle ear swabs, agent microorganisms, and their susceptibility to antibiotics were evaluated in 70 patients (65 males, 5 females; mean age 21.1+/-1.3 years; range 19 to 25 years) with chronic suppurative otitis media.
  
  
  RESULTS
  No bacteria were isolated in 14% of the patients. Of 60 patients in whom bacteria were isolated, the most common bacteria was Pseudomonas aeruginosa (23%), followed by Staphylococcus aureus (18%), and Proteus spp. (17%). P. aeruginosa strains were susceptible to ceftazidime and imipenem (100%), ciprofloxacin (92%), and amikacin and gentamycin (85%); S. aureus strains were susceptible to methicillin and vancomycin (100%), ciprofloxacin (91%), sulbactam-ampicillin (73%), and gentamycin and trimethoprim-sulfamethoxazole (63%). Proteus strains were susceptible to ciprofloxacin (100%), ceftazidime (90%), and imipenem and gentamycin (70%).
  
  
  CONCLUSIONS
  Appropriate knowledge of antibacterial susceptibility of microorganisms will contribute to rational antibiotic usage and the success of treatment for chronic suppurative otitis media.
authors.affiliation: Department of Infectious Diseases, Gümüşsuyu Military Hospital, Istanbul, Turkey. hcgul@yahoo.com
authors.forename: H Cem
authors.initials: HC
authors.lastname: Gül
authors.forename: Ali
authors.initials: A
authors.lastname: Kurnaz
authors.forename: Vedat
authors.initials: V
authors.lastname: Turhan
authors.forename: Oral
authors.initials: O
authors.lastname: Oncül
authors.forename: Alahattin
authors.initials: A
authors.lastname: Pahsa
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002442:Ceftazidime / Q000494:pharmacology / Q000627:therapeutic use; D002908:Chronic Disease; D024881:Drug Resistance, Bacterial; D005260:Female; D006090:Gram-Negative Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006094:Gram-Positive Bacteria / Q000187:drug effects* / Q000302:isolation & purification; D006801:Humans; D015378:Imipenem / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008826:Microbial Sensitivity Tests; D010035:Otitis Media, Suppurative / Q000188:drug therapy / Q000382:microbiology*; D011511:Proteus / Q000187:drug effects / Q000302:isolation & purification; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification
chemical_list: D000900:Anti-Bacterial Agents; D015378:Imipenem; D002442:Ceftazidime